We are a not-for-profit organization of pharmaceutical and biotechnology companies with the mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators and the broader R&D community.
July 2021
IQ DSLG Nitrosamine Working Group has recently published a new manuscript in Organic Process Research & Development entitled "Nitrosamine Reactivity: A Survey of Reactions and Purge Processes"
July 2021
Reports from nine IQ groups spanning the pharma development lifecycle provide an important framework for the industry to support future pandemic or unmet medical needs for the patients we serve.
May 2021
The IQ Drug Induced Liver Injury (IQ-DILI) Initiative invites pharma and bio tech companies to join the affiliate for 1-year trial basis.